Outcome of liver transplantation for hepatitis B: Report of a single center's experience
dc.contributor.author | Chu, Chi-Jen | en_US |
dc.contributor.author | Fontana, Robert John | en_US |
dc.contributor.author | Moore, Charles | en_US |
dc.contributor.author | Armstrong, Douglas R. | en_US |
dc.contributor.author | Punch, Jeffrey D. | en_US |
dc.contributor.author | Su, Grace L. | en_US |
dc.contributor.author | Magee, John C. | en_US |
dc.contributor.author | Merion, Robert M. | en_US |
dc.contributor.author | Lok, Anna Suk-Fong | en_US |
dc.date.accessioned | 2006-04-19T14:20:35Z | |
dc.date.available | 2006-04-19T14:20:35Z | |
dc.date.issued | 2001-08 | en_US |
dc.identifier.citation | Chu, Chi-Jen; Fontana, Robert J.; Moore, Charles; Armstrong, Douglas R.; Punch, Jeffrey D.; Su, Grace L.; Magee, John C.; Merion, Robert M.; Lok, Anna S.F. (2001)."Outcome of liver transplantation for hepatitis B: Report of a single center's experience." Liver Transplantation 7(8): 724-731. <http://hdl.handle.net/2027.42/35277> | en_US |
dc.identifier.issn | 1527-6465 | en_US |
dc.identifier.issn | 1527-6473 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/35277 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=11510019&dopt=citation | en_US |
dc.description.abstract | Results of liver transplantation (LT) for hepatitis B have improved significantly with the use of hepatitis B immune globulin (HBIG) and/or lamivudine. The aim of this study is to review the long-term outcome of patients who underwent LT for hepatitis B. Records of 41 patients who underwent LT for hepatitis B and survived 3 months or longer post-LT were reviewed. Twenty patients were administered no immunoprophylaxis or short-term intramuscular HBIG, whereas 21 patients were administered high-dose intravenous (IV) HBIG. Median post-LT follow-up in these 2 groups was 76 months (range, 4 to 155 months) and 25 months (range, 4 to 68 months), respectively. Hepatitis B recurred in 15 (75%) and 4 patients (19%) who underwent LT in the pre-HBIG and post-HBIG eras, respectively. Cumulative rates of recurrent hepatitis B at 1 and 3 years post-LT in these 2 groups were 66% and 77% and 20% and 20%, respectively ( P < .001). Recurrent hepatitis B in the post-HBIG era correlated with antibody to hepatitis B surface antigen titer less than 100 IU/L. Nine patients with recurrent hepatitis B were administered lamivudine for 13 to 49 months (median, 28 months); 6 patients continued to have stable or improved liver disease, whereas 3 patients developed virological breakthrough with slow deterioration of liver disease. Long-term IV HBIG is effective in preventing recurrent hepatitis B. The risk for recurrent hepatitis B is negligible after the first year post-LT. Among patients with no virological breakthrough, lamivudine can stabilize or improve liver disease for up to 4 years in patients with recurrent hepatitis B post-LT. | en_US |
dc.format.extent | 97190 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | W.B. Saunders | en_US |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Surgery | en_US |
dc.title | Outcome of liver transplantation for hepatitis B: Report of a single center's experience | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Medicine, Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI | en_US |
dc.contributor.affiliationum | Department of Medicine, Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI | en_US |
dc.contributor.affiliationum | Department of Surgery, Division of Transplant Surgery, University of Michigan Medical Center, Ann Arbor, MI | en_US |
dc.contributor.affiliationum | Department of Surgery, Division of Transplant Surgery, University of Michigan Medical Center, Ann Arbor, MI | en_US |
dc.contributor.affiliationum | Department of Surgery, Division of Transplant Surgery, University of Michigan Medical Center, Ann Arbor, MI | en_US |
dc.contributor.affiliationum | Department of Medicine, Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI | en_US |
dc.contributor.affiliationum | Department of Surgery, Division of Transplant Surgery, University of Michigan Medical Center, Ann Arbor, MI | en_US |
dc.contributor.affiliationum | Department of Surgery, Division of Transplant Surgery, University of Michigan Medical Center, Ann Arbor, MI | en_US |
dc.contributor.affiliationum | Department of Medicine, Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI ; Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Box 0362, Ann Arbor, MI 48109. Telephone: 734-615-4628; FAX: 734-936-7392 | en_US |
dc.identifier.pmid | 11510019 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/35277/1/500070811_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1053/jlts.2001.26062 | en_US |
dc.identifier.source | Liver Transplantation | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.